Literature DB >> 23594831

Risk assessment for incident heart failure in individuals with atrial fibrillation.

Renate B Schnabel1, Michiel Rienstra, Lisa M Sullivan, Jenny X Sun, Carlee B Moser, Daniel Levy, Michael J Pencina, João D Fontes, Jared W Magnani, David D McManus, Steven A Lubitz, Thomas M Tadros, Thomas J Wang, Patrick T Ellinor, Ramachandran S Vasan, Emelia J Benjamin.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is a strong risk factor for heart failure (HF); HF onset in patients with AF is associated with increased morbidity and mortality. Risk factors that predict HF in individuals with AF in the community are not well established. METHODS AND
RESULTS: We examined clinical variables related to the 10-year incidence of HF in 725 individuals (mean 73.3 years, 45% women) with documented AF in the Framingham Heart Study. Event rates for incident HF (n = 161, 48% in women) were comparable in women (4.30 per 100 person-years) and men (3.34 per 100 person-years). Age, body mass index, ECG LV hypertrophy, diabetes, significant murmur, and history of myocardial infarction were positively associated with incident HF in multivariable models (C-statistic 0.71; 95% confidence interval 0.67-0.75). We developed a risk algorithm for estimating absolute risk of HF in AF patients with good model fit and calibration (adjusted calibration χ2 statistic 7.29; P(χ2) = 0.61). Applying the algorithm, 47.6% of HF events occurred in the top tertile in men compared with 13.1% in the bottom tertile, and 58.4% in women in the upper tertile compared with 18.2% in the lowest category. For HF type, women had a non-significantly higher incidence of HF with preserved EF compared with men.
CONCLUSIONS: We describe advancing age, LV hypertrophy, body mass index, diabetes, significant heart murmur, and history of myocardial infarction as clinical predictors of incident HF in individuals with AF. A risk algorithm may help identify individuals with AF at high risk of developing HF.

Entities:  

Keywords:  Atrial fibrillation; Epidemiology; Heart failure; Risk score

Mesh:

Year:  2013        PMID: 23594831      PMCID: PMC3858114          DOI: 10.1093/eurjhf/hft041

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  22 in total

1.  The importance of whether atrial fibrillation or heart failure develops first.

Authors:  Marcelle D Smit; Marjolein L Moes; Alexander H Maass; Ismaël D Achekar; Peter P Van Geel; Hans L Hillege; Dirk J van Veldhuisen; Isabelle C Van Gelder
Journal:  Eur J Heart Fail       Date:  2012-06-25       Impact factor: 15.534

2.  A new scoring system for evaluating the risk of heart failure events in Japanese patients with atrial fibrillation.

Authors:  Shinya Suzuki; Koichi Sagara; Takayuki Otsuka; Shunsuke Matsuno; Ryuichi Funada; Tokuhisa Uejima; Yuji Oikawa; Junji Yajima; Akira Koike; Kazuyuki Nagashima; Hajime Kirigaya; Hitoshi Sawada; Tadanori Aizawa; Takeshi Yamashita
Journal:  Am J Cardiol       Date:  2012-05-22       Impact factor: 2.778

3.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

4.  Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.

Authors:  Gerard C M Linssen; Michiel Rienstra; Tiny Jaarsma; Adriaan A Voors; Isabelle C van Gelder; Hans L Hillege; Dirk J van Veldhuisen
Journal:  Eur J Heart Fail       Date:  2011-06-03       Impact factor: 15.534

5.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

6.  A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.

Authors:  Thomas J Wang; Joseph M Massaro; Daniel Levy; Ramachandran S Vasan; Philip A Wolf; Ralph B D'Agostino; Martin G Larson; William B Kannel; Emelia J Benjamin
Journal:  JAMA       Date:  2003-08-27       Impact factor: 56.272

7.  Survival after the onset of congestive heart failure in Framingham Heart Study subjects.

Authors:  K K Ho; K M Anderson; W B Kannel; W Grossman; D Levy
Journal:  Circulation       Date:  1993-07       Impact factor: 29.690

8.  Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study.

Authors:  Tatjana S Potpara; Marija M Polovina; Marina M Licina; Jelena M Marinkovic; Gregory Y H Lip
Journal:  Eur J Heart Fail       Date:  2013-01-09       Impact factor: 15.534

9.  The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.

Authors:  P E Carson; G R Johnson; W B Dunkman; R D Fletcher; L Farrell; J N Cohn
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

10.  Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; S Bertil Olsson; Gregory Y H Lip; A John Camm; Günter Breithardt; Alessandro Capucci; Joan G Meeder; Martin H Prins; Samuel Lévy; Harry J G M Crijns
Journal:  Am Heart J       Date:  2007-06       Impact factor: 4.749

View more
  34 in total

1.  Association of Atrial Fibrillation and Cancer.

Authors:  Faisal Rahman; Darae Ko; Emelia J Benjamin
Journal:  JAMA Cardiol       Date:  2016-07-01       Impact factor: 14.676

2.  Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry.

Authors:  Yoshimori An; Masahiro Esato; Mitsuru Ishii; Moritake Iguchi; Nobutoyo Masunaga; Hikari Tsuji; Hiromichi Wada; Koji Hasegawa; Hisashi Ogawa; Mitsuru Abe; Gregory Y H Lip; Masaharu Akao
Journal:  Heart Vessels       Date:  2018-05-24       Impact factor: 2.037

Review 3.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 4.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

Review 5.  Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis.

Authors:  Darae Ko; Faisal Rahman; Renate B Schnabel; Xiaoyan Yin; Emelia J Benjamin; Ingrid E Christophersen
Journal:  Nat Rev Cardiol       Date:  2016-04-07       Impact factor: 32.419

6.  Modifiable Risk Factors for Incident Heart Failure in Atrial Fibrillation.

Authors:  Neal A Chatterjee; Claudia U Chae; Eunjung Kim; M Vinayaga Moorthy; David Conen; Roopinder K Sandhu; Nancy R Cook; I-Min Lee; Christine M Albert
Journal:  JACC Heart Fail       Date:  2017-06-14       Impact factor: 12.035

7.  Physical Activity Is Associated With Reduced Left Ventricular Mass in Obese and Hypertensive African Americans.

Authors:  Daisuke Kamimura; Paul D Loprinzi; Wanmei Wang; Takeki Suzuki; Kenneth R Butler; Thomas H Mosley; Michael E Hall
Journal:  Am J Hypertens       Date:  2017-06-01       Impact factor: 2.689

Review 8.  Global epidemiology of atrial fibrillation.

Authors:  Faisal Rahman; Gene F Kwan; Emelia J Benjamin
Journal:  Nat Rev Cardiol       Date:  2014-08-12       Impact factor: 32.419

9.  High Plasma Glutamate and a Low Glutamine-to-Glutamate Ratio Are Associated with Increased Risk of Heart Failure but Not Atrial Fibrillation in the Prevención con Dieta Mediterránea (PREDIMED) Study.

Authors:  Christopher Papandreou; Pablo Hernández-Alonso; Mònica Bulló; Miguel Ruiz-Canela; Jun Li; Marta Guasch-Ferré; Estefanía Toledo; Clary Clish; Dolores Corella; Ramon Estruch; Montserrat Cofán; Montserrat Fitó; Cristina Razquin; Fernando Arós; Miquel Fiol; José M Santos-Lozano; Lluís Serra-Majem; Liming Liang; Miguel A Martínez-González; Frank B Hu; Jordi Salas-Salvadó
Journal:  J Nutr       Date:  2020-11-19       Impact factor: 4.798

Review 10.  Heart Failure in Women--Insights from the Framingham Heart Study.

Authors:  Satish Kenchaiah; Ramachandran S Vasan
Journal:  Cardiovasc Drugs Ther       Date:  2015-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.